Personalized support begins with MyAlcon Together
The MyAlcon Together Patient Support program has been designed to help meet each patient's unique needs and help them get the most out of treatment with ROCKLATAN®
Customizable program offerings include:
Personalized nurse support that can help educate patients about their ROCKLATAN® prescription
Nurses provide personalized telephone support and education in over 200 languages to answer general questions about glaucoma and their IOP-lowering treatment
Patients can save on prescriptions with the Alcon Savings Card
Eligible, commercially insured patients may pay as little as $30 with the Savings Card*
Tips, reminders, and resources that may help keep their ROCKLATAN® treatment on track
Patients can receive text and email messages with tips for instilling drops, prescription refills, and other useful resources to help them stay on top of their prescription
Encourage your patients to enroll in the MyAlcon Together Patient Support program
*Restrictions apply. Patients with federal or state prescription coverage, such as Medicare or Medicaid, are not eligible for the Savings Card. See AlconRxSavings.com for full terms & conditions.
Alcon is committed to supporting patient access to medications
IOP=Intraocular pressure.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Epithelial corneal edema, described as honeycomb or bullous, has been reported in some patients with pre-existing corneal stromal edema or following ocular procedures that could affect corneal endothelial function. Epithelial corneal edema typically resolves upon discontinuation of ROCKLATAN®. Advise patients to notify their physician if they experience eye pain or decreased vision while using ROCKLATAN®.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.
- Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
- Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
- Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
- There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
- Contact lenses should be removed prior to the administration of ROCKLATAN® and may be reinserted 15 minutes after administration.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Adverse Reactions
The most common ocular adverse reaction observed in controlled clinical studies with ROCKLATAN® was conjunctival hyperemia which was reported in 59% of patients. Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions reported were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.
Please click here for the ROCKLATAN® Full Prescribing Information.